Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

In this study, researchers identified indometacin as a suitable active ingredient for a combination gel aimed at treating mastopathy and preventing breast cancer, establishing its concentration using literary analysis, marketing research, and in vitro biopharmaceutical methods.

This article reviews the challenges and differing perspectives on implementing cancer care pathways, highlighting an ASCO task force's recommendation for flexibility that met resistance due to administrative burdens and regional variations.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This report discusses the use of intralesional cidofovir and suggests it might be a viable option for treating SCC due to its successful outcome without observed systemic toxicity in this case.

This review discusses the role of the BAFF system in autoimmune diseases and highlights its therapeutic potential, emphasizing the need for disease-specific clinical trials to improve treatment strategies.

This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

This case report details two consanguineous patients with cerebral autosomal recessive arteriopathy, both having the same HTRA1 gene mutation, but exhibiting different clinical presentations, including one with epileptic seizures and lobar hemorrhages—previously undocumented in this condition.

Tofacitinib might be used to treat hair loss.

This review describes techniques to manage intraoperative floppy iris syndrome linked to alpha-1 blocker use in cataract surgery, highlighting the need for patient disclosure of medication use but reports no new clinical results.

This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

This study found that Biobran MGN-3 significantly reduced chemotherapy-induced tiredness, anorexia, nausea, and hair loss, improving quality of life in breast cancer patients undergoing treatment.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This literature review on JAK inhibitors reports that ocular side effects are rare but could be significant, with an inability to establish a causal link. Clinicians are advised to monitor such adverse events and report them to drug safety agencies.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

In this case report, a 60-year-old man with rheumatoid arthritis and sudden hair whitening was treated with baricitinib, showing significant hair repigmentation and regrowth in 8 months, suggesting potential for baricitinib in managing canities subita, especially when linked to alopecia areata.

This study found that a 50% ethanolic extract of Adiantum capillus had significant analgesic and anti-inflammatory effects in animals, particularly at the highest tested dose of 300 mg/kg.